03:46 AM EST, 11/04/2024 (MT Newswires) -- QIAGEN ( QGEN ) said Monday that the US Food and Drug Administration has approved for clinical use the company's QIAstat-Dx panel for meningitis and encephalitis.

The approval marks the fourth FDA-approved QIAstat-Dx panel in 2024, following clearances for a gastrointestinal panel and two respiratory panels, the company said.

The QIAstat-Dx system delivers results in about an hour, compared with at least 24 hours for traditional microbiological testing, according to Qiagen ( QGEN ).